secwatch.observer — SEC 8-K summary
======================================

Issuer:     INOVIO PHARMACEUTICALS, INC. (INO)
CIK:        0001055726
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001193125-23-274515
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INOVIO gets FDA breakthrough therapy for INO-3107; BLA on accelerated path without Phase 3 trial
--------------------------------------------------------------------------------

- FDA granted Breakthrough Therapy designation for INO-3107 to treat Recurrent Respiratory Papillomatosis (RRP).
- FDA confirmed Phase 1/2 trial data can support BLA submission under accelerated approval; no Phase 3 required.
- Cash, cash equivalents and short-term investments of $167.5M as of September 30, 2023.
- INOVIO planning to submit BLA under accelerated approval; type B meeting requested for Q4 2023.
- Commercialization strategy accelerated for potential earlier launch of INO-3107 if approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1055726/000119312523274515/0001193125-23-274515-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1055726/000119312523274515/d295356d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-274515

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer